Literature DB >> 22448505

Standing sedation in captive zebra (Equus grevyi and Equus burchellii).

Mark Hoyer1, Sara de Jong, Frank Verstappen, Marno Wolters.   

Abstract

Nine Grevy's zebras (Equus grevyi) and three Burchell's zebras (Equus burchellii) were immobilized in a standing position a total of 70 times for minor, nonpainful procedures over a 9-yr period. Standing sedation was successfully obtained with a combination of detomidine and butorphanol on 47 occasions (67.1%). Detomidine i.m. (median 0.10 mg/kg; range: 0.07-0.21) was administered by dart, followed 10 min later by butorphanol i.m. (median 0.13 mg/kg; range 0.04-0.24). The dosages were varied depending on the initial demeanor of the animal. On 23 occasions (32.9%), small amounts of etorphine (median 2.5 microg/kg; range 1.1-12.3 microg/kg) plus acepromazine (median 10 microg/kg; range 4.4-50 microg/kg) (as in Large Animal-Immobilon) had to be administered i.m. to gain sufficient sedation. In these latter cases, the animals were either excited or known for their aggressive character. The zebras were sufficiently immobilized for the length of most procedures (<45 min) without supplementation. At the end of the procedure, the animals were given atipamezole (2 mg per 1 mg detomidine used) and naltrexone (0.1 mg/kg) to reverse the sedative effects, irrespective of whether etorphine was used or not. Standing sedation, using the combination of the alpha-2 agonist detomidine and the partial agonist-antagonist opioid butorphanol (in some cases supplemented with etorphine + acepromazine), proved to be a very efficacious and safe method to be used in zebras under zoo conditions for short-lasting, nonpainful procedures.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22448505     DOI: 10.1638/2010-0093.1

Source DB:  PubMed          Journal:  J Zoo Wildl Med        ISSN: 1042-7260            Impact factor:   0.776


  1 in total

1.  Immobilization of captive plains zebras (Equus quagga) with a combination of etorphine hydrochloride, acepromazine, and xylazine hydrochloride.

Authors:  Tithipong Plangsangmas; Hathaipat Rattanathanya; Wanlaya Tipkantha; Saowaphang Sanannu; Umaporn Maikaew; Jessada Thaeonoen; Bencharong Sangkharak; Pornpiroon Chinson; Watcharin Hin-On; Nathavut Kanatiyanont; Boripat Siriaroonrat; Nantarika Chansue; Parntep Ratanakorn
Journal:  J Vet Med Sci       Date:  2021-12-03       Impact factor: 1.267

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.